机器人激素和自主调节用于2型糖尿病:阴茎插曲和肝交感切除术
Alcides Jose Branco Filho1, Marcos Brioschi2,3, Gabriel Carneiro Brioschi4,5
1Alcides Branco Medical Associates Clinic, Curitiba, Brazil.
Frontiers in surgery
|December 25, 2025
概括
新型机器人手术结合激素调节和神经向来改善2型糖尿病 (T2DM) 的结果. 这些概念验证案例显示出解决T2DM患者的代谢和自主功能障碍的希望.
科学领域:
- 代谢手术 代谢手术
- 机器人手术 机器人手术
- 自主性功能障碍 自主性功能障碍
背景情况:
- 2型糖尿病 (T2DM) 涉及荷尔蒙失衡和自主功能障碍.
- 减肥手术可以改善血糖控制,但对自主调节的影响有限.
研究的目的:
- 介绍T2DM针对激素和交感机制的两种新型机器人手术策略.
- 探索用于优化T2DM中代谢结果的综合方法.
主要方法:
- 两名T2DM患者接受了不同的机器人手术:以袖子胃切除和十二指肠排除 (案例1) 进行阴道间插入,或以双阴道间插入和肝交感切除 (案例2) 进行袖子胃切除.
- 程序使用机器人平台提高精度,旨在调节隐形素,葡萄糖和同情活动.
主要成果:
- 这两种机器人手术都成功完成,并发症最小.
- 案例1显示,在12个月后,体重显著减轻,胰岛素需求减少.
- 病例2显示睡眠呼吸暂停和下肢麻醉改善,表明自主性改善.
结论:
- 这些案例证明了将机器人代谢手术与T2DM自主调制相结合的安全性和可行性.
- 这种综合方法提供了一个潜在的策略,通过解决荷尔蒙和神经功能障碍来管理复杂的代谢障碍.
- 需要进一步的研究来验证这些发现及其长期疗效.
相关概念视频
Diabetes: Management and Pharmacotherapy
844
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
844
Glucagon-like Receptor Agonists
816
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
816
Diabetes Mellitus: Overview and Type I Subtype
4.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K
Insulin: Dosing Regimen and Adverse Effects
649
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
649
Chronic Pancreatitis II: Collaborative Care
284
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
284


